FI973063A7 - Guaniinijohdannainen - Google Patents

Guaniinijohdannainen Download PDF

Info

Publication number
FI973063A7
FI973063A7 FI973063A FI973063A FI973063A7 FI 973063 A7 FI973063 A7 FI 973063A7 FI 973063 A FI973063 A FI 973063A FI 973063 A FI973063 A FI 973063A FI 973063 A7 FI973063 A7 FI 973063A7
Authority
FI
Finland
Prior art keywords
guanine derivative
hydrochloride
guanine
derivative
oxopurin
Prior art date
Application number
FI973063A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973063A0 (fi
FI973063L (fi
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973063(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of FI973063A0 publication Critical patent/FI973063A0/fi
Publication of FI973063L publication Critical patent/FI973063L/fi
Publication of FI973063A7 publication Critical patent/FI973063A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
FI973063A 1995-01-20 1996-01-19 Guaniinijohdannainen FI973063A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (3)

Publication Number Publication Date
FI973063A0 FI973063A0 (fi) 1997-07-18
FI973063L FI973063L (fi) 1997-09-18
FI973063A7 true FI973063A7 (fi) 1997-09-18

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973063A FI973063A7 (fi) 1995-01-20 1996-01-19 Guaniinijohdannainen

Country Status (40)

Country Link
US (1) US6107302A (https=)
EP (1) EP0804436B1 (https=)
JP (1) JP3176633B2 (https=)
KR (1) KR100376074B1 (https=)
CN (1) CN1049893C (https=)
AP (1) AP662A (https=)
AR (1) AR002270A1 (https=)
AT (1) ATE302777T1 (https=)
AU (1) AU702794B2 (https=)
BG (1) BG63393B1 (https=)
BR (1) BR9606768A (https=)
CA (1) CA2210799C (https=)
CY (1) CY2531B1 (https=)
CZ (1) CZ297065B6 (https=)
DE (1) DE69635106T2 (https=)
DK (1) DK0804436T3 (https=)
EA (1) EA000364B1 (https=)
EE (1) EE03528B1 (https=)
ES (1) ES2248806T3 (https=)
FI (1) FI973063A7 (https=)
GB (1) GB9501178D0 (https=)
GE (1) GEP20001940B (https=)
HR (1) HRP960024B1 (https=)
HU (1) HU222993B1 (https=)
IL (1) IL116831A (https=)
IN (1) IN182468B (https=)
IS (1) IS2268B (https=)
NO (1) NO315558B1 (https=)
NZ (1) NZ298851A (https=)
OA (1) OA10499A (https=)
PL (1) PL182175B1 (https=)
RO (1) RO118693B1 (https=)
RS (1) RS49518B (https=)
SI (1) SI0804436T1 (https=)
SK (1) SK285329B6 (https=)
TR (1) TR199700656T1 (https=)
UA (1) UA46001C2 (https=)
UY (1) UY25779A1 (https=)
WO (1) WO1996022291A1 (https=)
ZA (1) ZA96449B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
HUP0500753A3 (en) * 2001-09-07 2006-05-29 Teva Pharma Crystalline forms of valacyclovir hydrochloride
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh) * 2001-11-14 2007-03-28 特瓦制药工业有限公司 伐昔洛韦的合成与纯化
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽(常州)药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
IS4527A (is) 1997-07-15
IL116831A (en) 1998-10-30
NO973326D0 (no) 1997-07-18
PL182175B1 (pl) 2001-11-30
AU702794B2 (en) 1999-03-04
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
JP3176633B2 (ja) 2001-06-18
EE9700175A (et) 1998-02-16
ZA96449B (en) 1996-08-07
RS49518B (sr) 2006-10-27
TR199700656T1 (xx) 1998-03-21
AP9701058A0 (en) 1997-10-31
ES2248806T3 (es) 2006-03-16
US6107302A (en) 2000-08-22
HU222993B1 (hu) 2004-01-28
CZ229497A3 (en) 1997-12-17
MX9705462A (es) 1997-10-31
PL321326A1 (en) 1997-12-08
EP0804436A1 (en) 1997-11-05
NO315558B1 (no) 2003-09-22
EA000364B1 (ru) 1999-06-24
AU4453996A (en) 1996-08-07
GEP20001940B (en) 2000-02-05
FI973063A0 (fi) 1997-07-18
AR002270A1 (es) 1998-03-11
EE03528B1 (et) 2001-10-15
CZ297065B6 (cs) 2006-08-16
BR9606768A (pt) 1997-12-30
CY2531B1 (en) 2006-04-12
GB9501178D0 (en) 1995-03-08
EP0804436B1 (en) 2005-08-24
KR19980701525A (ko) 1998-05-15
DE69635106T2 (de) 2006-06-08
BG101833A (bg) 1998-04-30
JPH11503718A (ja) 1999-03-30
DE69635106D1 (de) 2005-09-29
HUP9801836A2 (hu) 1999-05-28
UY25779A1 (es) 2000-08-21
DK0804436T3 (da) 2005-12-27
HRP960024B1 (en) 2005-08-31
HUP9801836A3 (en) 1999-06-28
UA46001C2 (uk) 2002-05-15
HRP960024A2 (en) 1997-10-31
FI973063L (fi) 1997-09-18
WO1996022291A1 (en) 1996-07-25
EA199700124A1 (ru) 1997-12-30
OA10499A (en) 2002-04-10
CA2210799A1 (en) 1996-07-25
KR100376074B1 (ko) 2003-06-02
SK285329B6 (sk) 2006-11-03
RO118693B1 (ro) 2003-09-30
IN182468B (https=) 1999-04-17
CN1179159A (zh) 1998-04-15
IS2268B (is) 2007-07-15
NO973326L (no) 1997-09-16
YU3396A (sh) 1998-12-23
ATE302777T1 (de) 2005-09-15
SI0804436T1 (sl) 2006-02-28
IL116831A0 (en) 1996-05-14
NZ298851A (en) 1999-01-28
SK96597A3 (en) 1998-02-04
CA2210799C (en) 2008-06-10
AP662A (en) 1998-08-19

Similar Documents

Publication Publication Date Title
FI973063A7 (fi) Guaniinijohdannainen
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
PL319605A1 (en) Novel benzoxazoles
DE69830504D1 (de) Antithrombotische mitteln
DK0859766T3 (da) Chirale methylphenyloxazolidinoner
FI931332A0 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
PT1043310E (pt) Derivados de bifenilamidina
NO20021937D0 (no) Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer
NO982237D0 (no) Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
FI20000553L (fi) Proteaasi-inhibiittoreina käyttökelpoisten 4-hydroksi-2-oksopyraanijohdannaisten valmistusmenetelmä
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
FI973644A0 (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
EE200000024A (et) Meetod alküüloksüfuranooni amiinderivaatide valmistamiseks, sel meetodil saadud ühendid ja nende kasutamine
FI913951A7 (fi) Menetelmä kiteisen 7- -amino-3-(5-karboksimetyyli-4-metyyli-1,3-tiatsol-2-yyli-tiometyyli)-kef-3-emi-4-karboksyylihapon (TACS) valmistamiseksi
MY127470A (en) Process for the synthesis of chloropurine intermediates
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
BG104964A (bg) Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни
FI880868A0 (fi) Välituotteina käyttökelpoisia tetratsoliyhdisteitä
SE9901340D0 (sv) Novel process
BR0117362B1 (pt) processo para a preparação de um composto derivado de 2-piridilmetilamina de fórmula geral (v)
TR200001161A2 (tr) 8-Siklopentil-6-etil-3-[ikame edilmiş]-5, 8-Dihidro-4H-1, 2, 3A, 7, 8-Pentaaza-As-Indasenlerin hazırlandığı işlem ve burada yararlı ara bağlar.
AU6248790A (en) Process for the preparation of 2-(2-furyl)ethanol amine
SE9901338D0 (sv) Novel process

Legal Events

Date Code Title Description
FD Application lapsed